Open AccessContraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015
Author(s) -
Horibe Megumi,
Hane Yuuki,
Abe Junko,
Matsui Toshinobu,
Kato Yamato,
Ueda Natsumi,
Sasaoka Sayaka,
Motooka Yumi,
Hatahira Haruna,
Hasegawa Shiori,
Kinosada Yasutomi,
Hara Hideaki,
Nakamura Mitsuhiro
Publication year - 2018
Publication title -
nursing open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.55
H-Index - 12
ISSN - 2054-1058
DOI - 10.1002/nop2.121
Subject(s) - drospirenone , medicine , postpartum depression , adverse event reporting system , adverse effect , odds ratio , obstetrics , levonorgestrel , depression (economics) , postpartum period , desogestrel , retrospective cohort study , childbirth , gynecology , population , family planning , pregnancy , environmental health , genetics , macroeconomics , economics , research methodology , biology
Aim Postpartum depression is a mood disorder that commonly affects women during the early postpartum period. The objective of this study was to analyse the association of postpartum depression with drugs (including contraceptive devices and implants) with spontaneously reported adverse events reported in the US Food and Drug Administration Adverse Event Reporting System database. Design Retrospective study. Method Reports of postpartum depression events between 2004–2015 were analysed with a reporting odds ratio ( ROR ) algorithm. The Medical Dictionary for Regulatory Activities was used to identify postpartum depression. Results The reporting odds ratios (95% confidence intervals, CI ) of levonorgestrel (an intrauterine device with progestogen), etonogestrel (a hormonal contraceptive implant), sertraline and drospirenone (an oral contraceptive) were 12.5 (8.7–18.0), 14.0 (8.5–22.8), 12.2 (6.5–23.1) and 5.4 (2.7–10.9) respectively. Among the drugs in the US Food and Drug Administration Adverse Event Reporting System database, the use of contraceptives or an intrauterine device with progestogen might convey risk for postpartum depression.